PT-141 10mg is a synthetic melanocortin receptor agonist research peptide supplied as a single lyophilized vial. Manufactured for consistent potency, stability, and controlled research applications.
Format10mg Vial
Pack Size Selected: 5 Pack
Pay with Interac e-Transfer or Crypto
HPLC verified. COA on file for this batch
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
PT-141 (Bremelanotide) is a synthetic melanocortin peptide and direct metabolite of Melanotan II. Produced through removal of the C terminal amide group from the MT-2 structure, that achieved FDA approval under the brand name Vyleesi for hypoactive sexual desire disorder, contributing a well documented human clinical literature base that distinguishes it from most research peptide compounds. iLab Pharma’s 10mg lyophilized vial delivers a higher concentration standalone presentation than CSD’s Hudson Science 10mg nasal spray at equivalent total compound with the lyophilized injectable vial format serving distinct research purposes from the intranasal delivery system.
The 10mg lyophilized vial and 10mg nasal spray serve complementary research purposes within CSD’s PT-141 range. The nasal spray format’s intranasal delivery provides proximity to the olfactory epithelium and potential direct CNS access via the olfactory nerve pathway. A pharmacokinetically relevant advantage for PT-141’s primary MC3R and MC4R hypothalamic targets where central nervous system receptor engagement is the principal research variable. The lyophilized vial’s reconstitute format supports subcutaneous parenteral administration research. The administration route most extensively documented in PT-141’s clinical trial literature including the Vyleesi approval studies alongside in vitro melanocortin receptor binding studies and comparative bioavailability research between intranasal and parenteral delivery at matched concentration.
PT-141’s most pharmacologically significant research characteristic is its PDE5 independent mechanism of action, producing central nervous system mediated arousal response through hypothalamic MC4R activation and downstream dopaminergic pathway modulation rather than the peripheral vascular smooth muscle relaxation mechanism of PDE5 inhibitors like sildenafil. This CNS mediated mechanism makes PT-141 a distinctly different research tool from vascular targeted sexual health compounds. Operating at the hypothalamic level where desire and arousal initiation occurs rather than at the peripheral vascular level where physical response is facilitated. The MC3R and MC4R selectivity that produces this CNS focused profile also explains PT-141’s significantly reduced MC1R melanogenic activity compared to Melanotan II; making it the preferred melanocortin research compound for sexual health and CNS arousal pathway studies where pigmentation endpoint confounding is an unwanted research variable.
iLab Pharma formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD stocks PT-141 across two formats: this iLab Pharma 10mg lyophilized vial and the Hudson Science 10mg nasal spray, alongside Melanotan II across vial and nasal spray formats, giving researchers complete melanocortin receptor agonist delivery route and comparative compound flexibility from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.
Commonly researched alongside Melanotan II in comparative melanocortin receptor selectivity and central nervous system signaling studies. Browse CSD’s full peptide range for complete sourcing.
I was a bit hesitant at first to try this but went ahead and got 1 - 10 mg vial to see how it would go. I did my research and as far as I could tell, this 10 mg vial will give you between 4-6 doses. My first dose was subcutaneous injection of 1.75mg and it took about 45 minutes to notice anything. It was going to be interesting to see because I took this and had no sexual activity with a partner planned. in fact, I don't have a consistent sexual partner right now, so I'm flying solo. So, about 45 min in, I did notice that I had become semi erect and it did not take much to make that into a rock hard boner. I also noticed feeling quite horny and ready to go. This feeling lasted fora good 6-8 hours and at one point was finding it difficult to control the erections. It's been decades since I've had a boner in public or get hard in a situation where you might not normally get hard.(sitting in rush hour traffic) I also felt heightened erotic sensation when playing with myself. when I take this again, I will reduce the dose to maybe 1.25 to 1.35 mg and see how that goes. Would I buy this again? YES!!!
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist acting selectively on MC3R and MC4R receptors in the central nervous system to enhance sexual arousal and libido through central hypothalamic and limbic pathways. Unlike PDE5 inhibitors such as Sildenafil and Tadalafil which act peripherally on vascular smooth muscle to facilitate erection, PT-141 acts centrally on the brain's sexual arousal circuitry, producing sexual desire and arousal independent of vascular mechanisms. It is FDA approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women, and is extensively researched for both male and female sexual dysfunction, particularly cases refractory to PDE5 inhibitors where inadequate central arousal rather than vascular insufficiency is the underlying mechanism.
PT-141 and PDE5 inhibitors address sexual dysfunction through fundamentally different mechanisms. PDE5 inhibitors enhance penile blood flow in response to sexual stimulation by preventing cGMP breakdown, they require existing sexual arousal and intact nitric oxide signaling to produce erection. PT-141 acts centrally on melanocortin receptors in the hypothalamus and limbic system to generate sexual desire and arousal; producing both central arousal and subsequent physical response independent of nitric oxide and vascular mechanisms. PT-141 is effective in cases where PDE5 inhibitors are insufficient due to inadequate central arousal, and the two compound classes are complementary; PT-141 addressing the desire/arousal component while PDE5 inhibitors address the vascular/erectile mechanics.
Reconstitute the 10mg lyophilized vial with bacteriostatic water (BAC water): add BAC water slowly along the glass wall, swirl gently to dissolve, do not shake. Adding 2mL of BAC water produces a concentration of 5mg per mL at this concentration, 0.3mL delivers 1.5mg, 0.4mL delivers 2mg, and 1mL delivers 5mg. Common research doses range from 1–2mg subcutaneously administered 45–90 minutes before the research window; the 10mg vial provides 5–10 research doses depending on per dose volume. Some research protocols use higher doses of up to 2mg for subjects with insufficient response at 1mg. Store reconstituted solution refrigerated between 2–8°C and use within 30 days.
PT-141's most commonly reported side effects in research are nausea, occurring in approximately 40% of subjects at doses of 1.75mg in clinical trials and flushing, which is dose dependent and related to melanocortin receptor activation in peripheral vasculature. Transient blood pressure elevation has also been observed, typically peaking 30–60 minutes after injection and resolving within 12 hours. Starting at lower doses of 0.5–1mg and titrating upward in subsequent research sessions allows assessment of individual tolerance before committing to the full 1.75–2mg dose. Nausea severity can be reduced by administering the injection 90 minutes rather than 45 minutes before the research window and ensuring adequate hydration.
Yes! This batch has been independently HPLC tested by an accredited third party laboratory confirming compound identity as Bremelanotide (PT-141) and content accuracy at 10mg per vial. A certificate of analysis is available.
![NAD+ - 1,000mg [Aging]](https://www.canadasteroiddepot.is/wp-content/uploads/2026/03/hudson-nad-300x300.png)
![GLP-3 RTA [Triple G] - 10mg](https://www.canadasteroiddepot.is/wp-content/uploads/2026/03/HUD-GLP3-10-300x300.png)
